MTD · Mettler Toledo International Inc/
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 31, 2026TL;DR. Mettler-Toledo reported strong Q2 results with local currency sales up 6% (above ~3% guidance) and adjusted EPS of $11.46, up 14%. The company raised full-year 2026 local currency sales growth guidance to ~4-5% and adjusted EPS growth to 10-11% (from prior 8-10%), while also lifting share repurchases to $875 million.
- + Raised full-year 2026 local currency sales growth guidance to approximately 4-5% from prior approximately 4%
- + Raised full-year 2026 adjusted EPS growth guidance to 10-11% from prior 8-10%
- + Q2 local currency sales grew 6%, above prior guidance of approximately 3%, with organic local currency growth of 4%
- + Adjusted EPS of $11.46 rose 14% year-over-year
- + Adjusted operating margin expanded 50 basis points to 29.3%, or up 100 basis points excluding currency
- + Increased full-year share repurchases to $875 million from an annualized $825 million level in the first half
- − Reported Americas sales declined 3% in U.S. dollars in Q2
- − Product inspection organic sales growth was only 1% in the quarter due to timing of customer projects
- − A $28 million one-time refund to customers reduced reported net sales by 3% in Q2
- − Year-to-date adjusted free cash flow of $367 million was negatively impacted by $55 million of higher tax payments versus prior year
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MTD
this stock
Mettler Toledo International Inc/
|
$30.29B | +6.2% | +4.0% | 34.1 | 3.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +12.6% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -7.5% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +78.3% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +22.5% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MTD | -2.5% | +8.3% | +11.8% | -2.0% | +6.2% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -2.1% | +8.4% | -0.7% | -2.2% | -5.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.